Departments of 1 Pediatrics, 2 Medicine, and 3 Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106-4951
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Results of previous
studies indicated that treatment of diabetic rats (induced by
streptozotocin) with cobalt chloride
(CoCl2) resulted in a
significant decrement in serum glucose concentration. The present study
was designed to determine the potential role of enhanced glucose uptake
vs. decreased glucose production in the above response. The rate of
systemic appearance of glucose, measured under fasting
conditions using
[3-3H]glucose tracer,
was reduced from 35.5 ± 2.5 to 17.5 ± 1.8 µmol · kg1 · min
1
in diabetic rats treated with 2 mM
CoCl2 added to the drinking water
for 10-14 days (P < 0.01).
Tissue accumulation of intravenously administered
2-deoxy-[14C]glucose
was significantly reduced in kidney and eye of diabetic rats treated
with CoCl2, whereas the uptake
remained unchanged in several other tissues including cerebrum, red and
white skeletal muscle, heart, and liver. The relative content of
phosphoenolpyruvate carboxykinase (PEPCK) mRNA was increased
3.1-fold in livers of diabetic compared with normal rats
(P < 0.001), and treatment of
diabetic rats with CoCl2 decreased
hepatic PEPCK mRNA levels to normal. The content of PEPCK mRNA in the
liver was decreased by 33% in
CoCl2-treated normal rats
(P < 0.05). Treatment with CoCl2 resulted in no change in
cAMP levels in the livers of either diabetic or normal rats. These
results suggest that the glycemia-lowering effect of
CoCl2 is mediated by reductions in
the rate of systemic appearance of glucose and hepatic gluconeogenesis.
glucose uptake; phosphoenolpyruvate carboxykinase mRNA; adenosine 3',5'-cyclic monophosphate
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CELLULAR UPTAKE and metabolism of glucose are of critical importance in the maintenance of homeostasis and energy production. The first step in glucose metabolism is its transport across the plasma membranes, a function that is "rate limiting" in many cells and tissues (5, 12). Transmembrane transport of glucose is mediated by a family of Na+-independent glycoprotein glucose transporter (GLUT) molecules that are expressed in a tissue-specific manner (20, 23). Of these, GLUT-4 and GLUT-1 are especially relevant to diabetes because they mediate insulin-stimulated and basal (insulin-independent) uptake of glucose, respectively (20, 23).
Results of our previous studies in Clone 9 cells, C2C12 myoblasts, and 3T3-L1 preadipocytes demonstrated that inhibition of oxidative phosphorylation by hypoxia and by inhibitors of oxidative phosphorylation such as cyanide and azide causes a stimulation of glucose transport and an induction of GLUT-1 gene expression (2, 19, 25, 26). We have also shown in the above cells that, similar to other "hypoxia-responsive genes" (8), GLUT-1 gene expression is augmented by cobalt chloride (CoCl2) employed under normoxic conditions (2). On the basis of these findings, we recently explored the possibility that exposure of diabetic and normal rats to CoCl2 will similarly enhance tissue GLUT-1 expression and tissue glucose uptake and thereby lead to a lowering of blood glucose (31). The results showed that treatment of diabetic rats [induced by streptozotocin (STZ)] with 2 mM CoCl2 added to the drinking water resulted in a lowering of nonfasting serum glucose levels from 35 ± 2 to 21 ± 2 mM; a smaller decrement in glycemia of normal rats treated with CoCl2 was not significant. Treatment with CoCl2 was associated with a 1.3- to 2.9-fold increase in GLUT-1 mRNA content of ventricular myocardium, renal cortex, skeletal muscle, cerebrum, and liver of both diabetic and normal rats. Although GLUT-1 and glucose transport were not measured in that study (31), the results are consistent with the possibility that the glycemia-lowering effect of CoCl2 may be mediated by enhanced expression of GLUT-1 mRNA, GLUT-1 protein, and glucose uptake. However, treatment with CoCl2 could also have reduced hepatic glucose output and thus lowered blood glucose.
The present study was therefore conducted to determine the potential role of enhanced tissue glucose uptake vs. decreased systemic glucose production in mediating the glycemia-lowering effect of CoCl2 in diabetic rats. The rate of systemic appearance (Ra) of glucose was measured under fasting conditions by tracer dilution in diabetic and normal rats treated or not treated with CoCl2. We also determined the effect of CoCl2 on the relative abundance of hepatic phosphoenolpyruvate carboxykinase (PEPCK) mRNA and on the concentration of cAMP in the liver as a measure of changes in hepatic gluconeogenesis. The results indicate that the dominant effect of CoCl2 in reducing the glycemia of diabetic rats results from a reduction in the Ra of glucose and decreased hepatic gluconeogenesis.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials.
CoCl2 and other standard chemicals
were obtained from Sigma Chemical (St. Louis, MO). Reagent-grade ether
was obtained from Fisher (Pittsburgh, PA). The cAMP kit was obtained
from Amersham (Arlington Heights, IL).
[3-3H]glucose (10.4 Ci/mmol),
2-deoxy-[U-14C]glucose
(294 Ci/mmol), and
deoxy-[-32P]cytidine
(3,000 Ci/mmol) were obtained from DuPont-NEN Research Products
(Boston, MA). PE-50 polyethylene nontoxic tubing (ID, 0.58 mm; OD,
0.965 mm) was obtained from Becton-Dickinson (Sparks, MD). The rodent
sling jacket was obtained from Harvard Bioscience (South Natick, MA).
QuickPrep total RNA extraction kit and Quikhyb were purchased from
Pharmacia Biotech (Piscataway, NJ) and Stratagene (La Jolla, CA),
respectively. GeneScreen Plus hybridization membrane was obtained from
DuPont-NEN Life Sciences. The cDNA probe for the cytosolic form of
PEPCK was a 1.1-kb Pst
I/Pst I fragment from the 3' end
of the rat PEPCK cDNA, pPCK 10 (32). Kits for measurement of cAMP were
obtained from Amersham.
Animals. Male Sprague-Dawley rats weighing 225-250 g were obtained from Zivic Miller (Zelienople, PA). The animals were kept in a controlled environment that meets the requirements of the American Association for the Accreditation of Laboratory Animals. They had free access to rat chow (Purina), and water was administered on a 12:12-h light-dark cycle. The protocol was approved by the Institutional Animal Care and Use Committee.
Diabetes was induced by injection of a freshly prepared solution of STZ in saline at 60 mg/kg body wt in the tail vein (31). After 1 wk, a sample of blood was obtained from the tail vein to ensure the presence of diabetes (serum glucose >25 mM). One-half of the group of normal rats and one-half of the diabetic group were then placed on 2 mM CoCl2 in the drinking water for 12-16 days. During the ~2-wk period, normal and diabetic rats gained ~30 and ~15 g of weight, respectively, and treatment with CoCl2 resulted in no change in weight gained by diabetic rats. In a previous study employing various concentrations of CoCl2, we found that a similar group of diabetic rats treated with up to 4 mM CoCl2 for 7 wk gained ~100 g in body weight, a rate that was identical to that in diabetic rats not treated with CoCl2 (31). On the basis of the daily water intake, we estimate that diabetic and normal rats received a total dose of ~2 and ~1 mmol of CoCl2, respectively. Values for serum glucose, electrolytes, and other constituents summarized in Table 1 were measured in the hospital laboratory.
|
Measurement of Ra of glucose and of glucose uptake by tissues. These experiments were performed in different sets of animals from the ones described above; diabetes and treatment with CoCl2 were as indicated above. Indwelling arterial and venous catheters were placed 3-4 days before the tracer study. The animals were anesthetized with an intramuscular injection (0.1 ml/100 g body wt) of ketamine-acepromazine mixture (90 mg ketamine and 1 mg acepromazine per ml). PE-50 catheters were inserted in the right external jugular and left carotid artery under sterile conditions. The catheters were filled with an anticoagulant mixture of polyvinylpyrrolidone and heparin in isotonic saline (polyvinylpyrrolidone, 0.75 g; heparin, 25 units in 1 ml of isotonic saline). This polymer allows catheter patency for a week or more. The catheters were tunneled subcutaneously, and the distal end of the catheter was sutured to the dorsum of the rat's neck. The free end of the catheter was sealed, and the rat was placed in a Harvard rodent jacket sling, thus allowing the animal to move freely during the postoperative period. After surgery, rats were housed in individual cages and had free access to a standard diet (Purina rat chow) and water or CoCl2 solution as indicated.
Twenty-four to thirty hours before the infusion, food was removed from the animal cages. [3-3H]glucose in isotonic saline was given as a prime constant-rate infusion using a Harvard pump, starting at 11:00 AM. The priming dose was 1.5-2.0 µCi, and tracer was infused at the rate of 0.05-0.07 µCi · kg body wtMeasurement of cAMP levels in the liver. Groups of CoCl2-treated and untreated normal and diabetic rats separate from those used above were employed. Rats were decapitated after CO2-inhalation anesthesia. Livers were removed promptly and frozen immediately using liquid nitrogen or dry ice. cAMP determinations are based on a competition enzyme immunoassay as described by the manufacturer (Amersham). Approximately 100 mg of frozen liver were homogenized in 10 volumes of ice-cold 6% (wt/vol) trichloroacetic acid by means of a Teflon-glass homogenizer. After centrifugation at 2,000 g for 15 min at 4°C, a 250-µl aliquot of the supernatant was extracted five times with 1 ml of water-saturated diethyl ether. Two-hundred microliters of the aqueous phase were lyophilized and resuspended in 1 ml of the assay buffer supplied with the kit. cAMP determinations were carried out using 100-µl aliquots of samples, with standards ranging from 12.5 to 3,200 fmol/well.
Isolation of RNA and Northern blot analysis. Total RNA was extracted from livers of experimental animals using the QuickPrep total RNA extraction kit. Seventy-five to one-hundred milligrams of frozen liver (obtained as described above) were homogenized and treated as per the manufacturer's instructions. RNA samples (10 µg) were fractionated on formaldehyde-agarose gels and transferred to GeneScreen Plus membrane by capillary action. The membrane was hybridized with a randomly primed 32P-labeled rat PEPCK cDNA probe (32) and washed, and the radioactivity in each band was measured by video densitometry using a Molecular Dynamics phosphorimager. To ensure equal RNA loading of the lanes and to control for completeness of RNA transfer, ethidium bromide staining of ribosomal 28S and 18S bands on the gels and on the nitrocellulose paper was monitored throughout.
To compare the relative abundance of hepatic PEPCK mRNA among different experimental groups, the average densitometric measurement of PEPCK mRNA in normal rats not treated with CoCl2 was calculated and set to 1.0. Values obtained for all samples were then normalized against the mean value obtained for the control group.Analysis of data and statistical methods. Data on all four experimental groups, i.e., diabetic rats, diabetic rats treated with CoCl2, normal rats, and normal rats treated with CoCl2, are presented throughout. However, analysis of the potential effects of CoCl2 on any given parameter was performed in diabetic rats and normal rats treated (vs. not treated) with the agent. This was done because diabetes itself is associated with changes in some of the parameters being examined.
All experimental results are expressed as means ± SE. Unpaired Student's t-test was employed, and P < 0.05 was considered significant (27). ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effect of CoCl2 on the concentration of glucose and selected other constituents in the blood of diabetic and normal rats. Normal and diabetic rats gained ~30 and ~15 g, respectively, during the ~2 wk of study, and treatment with CoCl2 resulted in no change in the rate of weight gain by diabetic rats. Table 1 summarizes the effect of 10 days of treatment with CoCl2 on the concentration of several serum constituents in the four groups of rats. Rats in both diabetic groups were not fasted before obtaining blood samples. In both groups of normal rats, with the exception of serum glucose and insulin, values are from rats after a 24-h period of food deprivation. Blood glucose was determined under nonfasting conditions, because it was found in preliminary studies that blood glucose concentration in diabetic rats decreased to normal levels after a 24- to 30-h period of food deprivation. In accordance with our previous observations (31), treatment with CoCl2 resulted in a dramatic reduction of nonfasting glycemia of diabetic rats from 35.4 ± 2.8 to 21.2 ± 2.2 mM glucose (P < 0.01), whereas the agent resulted in no significant change in the serum glucose concentration of normal rats. In diabetic rats treated with CoCl2, there was a significant decrease in the concentration of bicarbonate and phosphate compared with diabetic rats not treated with the agent; the decrements in serum cholesterol and triglyceride in CoCl2-treated diabetic rats were not significant, although two diabetic rats that had not been treated with CoCl2 had lipemic serum. Treatment of normal rats with CoCl2 resulted in no measurable change in the concentration of any of the serum constituents. The concentrations of insulin and glucagon in the serum of diabetic rats treated or not treated with CoCl2 [both reported previously (31)] have also been included in Table 1. After 10 days of treatment with CoCl2, hematocrit values in both normal and diabetic rats rose equally from 37 ± 1 to 40 ± 1%.
Effect of CoCl2 on the
Ra of glucose in diabetic and normal rats.
The Ra was determined in all four
experimental groups after 24-30 h of food deprivation; the fasting
period resulted in a normalization of serum glucose concentration in
both groups of diabetic rats. Serum glucose concentrations during
measurement of Ra were 6.37 ± 0.22 and 6.04 ± 0.42 mM in diabetic and
CoCl2-treated diabetic rats,
respectively. Ra, expressed either
as micromoles per minute (data not shown) or as micromoles per minute
per kilogram body weight, was ~50% lower in diabetic animals treated
with CoCl2 (35.5 ± 2.5 vs.
17.5 ± 1.8 µmol · kg1 · min
1;
P < 0.01; Fig.
1). Ra
also was lower by ~35% in normal rats treated with
CoCl2 (from 47.5 ± 8.5 to 33.0 ± 3.0 µmol · kg
1 · min
1),
but the change was not significant (Fig. 1). Comparison of glucose
Ra values in diabetic vs. normal
rats [both groups not treated with
CoCl2] reveals no
significant difference between the two groups. Because the
concentration of glucose in the blood was constant during the 3-h
period of measurement of Ra, the
experimental results can be used to calculate the clearance of glucose
from the circulation. Glucose clearance was 0.89 ± 0.22 and 0.59 ± 0.07 ml · 100 g body
wt
1 · min
1
in normal and CoCl2-treated normal
rats, respectively (P > 0.1). It was
0.53 ± 0.04 and 0.26 ± 0.04 ml · 100 g body
wt
1 · min
1
in diabetic and CoCl2-treated
diabetic rats, respectively (P < 0.01).
|
Effect of CoCl2 on the rate of glucose
uptake by selected tissues in diabetic and normal rats.
After determination of Ra, glucose
uptake by several tissues of the same rats was measured by previously
described methods (6). Figure 2 summarizes
the amount of
2-deoxy-[14C]glucose
6-phosphate accumulated in tissues of diabetic rats not treated or
treated with CoCl2. It should be
noted that accumulation of glucose in tissues is a composite function
of transport and phosphorylation steps acting sequentially. Among the
tissues examined in the diabetic rat, heart and cerebrum exhibited high
rates of uptake (expressed as nmol · g tissue
wt1 · min
1).
Because only a small fraction of the eye represents the metabolically highly active cells of the retina, this tissue probably manifests the
highest rate of glucose uptake and metabolism. The kidney had an
intermediate rate of uptake, whereas the red and white gastrocnemius
muscle exhibited lower rates. Treatment of diabetic rats with
CoCl2 tended to increase the rate
of uptake of
2-deoxy-[14C]glucose
by heart and liver, whereas the uptake by cerebrum, kidney, muscle, and
eye was decreased; of the aforementioned changes, only the decrements
in uptake by the kidney and eye were significant.
|
|
Effect of CoCl2 on the content of PEPCK mRNA in the livers of diabetic and normal rats. We next examined the possibility that the activity of PEPCK, the key enzyme in the control of gluconeogenesis, might be suppressed as a result of exposure to CoCl2. Because PEPCK activity closely parallels PEPCK mRNA content (13), we measured the effect of CoCl2 treatment on the concentration of PEPCK mRNA in the liver. Two experimental protocols were employed. In the first, the relative abundance of PEPCK mRNA was measured in livers of nonfasted normal rats, diabetic rats, and diabetic rats treated with CoCl2 (Fig. 4A). Rats were not fasted because food deprivation increases PEPCK expression in normal rats. The content of PEPCK mRNA in the liver of diabetic rats was increased to 3.1-fold over that found in the liver of nontreated rats (P < 0.001). Treatment of diabetic rats with CoCl2 resulted in a significant reduction in the content of PEPCK mRNA in the liver to levels similar to those found in livers of normal rats not treated with CoCl2 (P > 0.4). In a separate set of experiments, we found that treatment of diabetic rats with CoCl2 under nonfasting conditions also decreased liver PEPCK mRNA content by approximately threefold (P < 0.05; data not shown). In the second protocol, the effect of CoCl2 on the level of PEPCK mRNA in the liver of nondiabetic animals was determined. In this experiment, normal and CoCl2-treated normal rats were deprived of food for 24 h to elicit an upregulation of PEPCK gene expression before study (Fig. 4B). The relative abundance of hepatic PEPCK mRNA was decreased by 33% in normal rats treated with CoCl2 compared with the control group (P < 0.05). The effect of CoCl2 was also determined in nonfasted normal and CoCl2-treated normal rats. PEPCK mRNA content was present at low levels in liver of fasted normal rats and decreased to below detectable levels in CoCl2-treated rats (data not shown).
|
Effect of CoCl2 on the levels of cAMP in the livers of diabetic and normal rats. It is well established that the expression of the gene for the cytosolic form of PEPCK in liver is highly regulated by several hormones, including glucagon, insulin, growth hormone, and cortisol, and by the nutritional status of the animal (10). Hence the reduction in the levels of PEPCK mRNA in livers of CoCl2-treated diabetic and normal animals summarized above may well be mediated by alterations in one or a combination of the above regulators. Because of the dominant and opposing roles of glucagon (acting through cAMP) and insulin on the regulation of PEPCK expression (9, 17) and because of our finding that the concentration of serum insulin is not changed as a result of treatment with CoCl2 in either diabetic or normal rats (Table 1), we examined the possibility that the concentration of hepatic cAMP is reduced in CoCl2-treated rats (Fig. 5). Under nonfasting conditions, the concentration of cAMP is slightly (but not significantly) lower in the livers of diabetic compared with normal rats (Fig. 5A) and decreases slightly as a result of CoCl2 treatment. Similarly, there was no significant change in cAMP levels in 24-h food-deprived normal rats treated with CoCl2 (Fig. 5B). Food deprivation in normal rats, however, was associated with a significant increase in hepatic cAMP levels from 625 ± 77 to 823 ± 40 pmol/g wet wt (P < 0.05).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The present study was prompted from the earlier observation that treatment of STZ-induced diabetic rats with CoCl2 results in a significant reduction in the serum glucose concentration (31). In principle, the glycemia-lowering effect of CoCl2 could be secondary to decreased systemic glucose production, increased tissue glucose uptake, or a combination of the two mechanisms. The observed induction of GLUT-1 mRNA in several tissues of CoCl2-treated rats suggested that enhanced glucose uptake may well play a dominant role in the above effect, although GLUT-1 expression and glucose transport were not measured in that study (31). The results of studies reported herein, however, indicate that the glycemia-lowering effect of CoCl2 is mediated by a reduction in the Ra of glucose and possibly gluconeogenesis. It is worth emphasizing that the results of the present study are internally consistent, i.e., the decrease in glycemia of CoCl2-treated diabetic rats is associated with a significant reduction in Ra and a decrease in liver PEPCK mRNA content. A reduction in calorie intake as the explanation for the reduction in glucose production is excluded by the observation that, in accordance with previous results (31), diabetic rats treated or not treated with CoCl2 gained weight at an equal rate during the 2-wk period of treatment.
Previous reports indicate that glucose Ra values in non-insulin-dependent diabetic subjects are higher than in normal controls (22), although the higher Ra values in diabetic subjects are documented under conditions in which the blood glucose concentrations are significantly higher than for nondiabetic controls (28). Ra values measured in the present study, whether expressed per animal or per unit body weight, were somewhat but not significantly lower in the diabetic animals. The reasons for this apparent discrepancy are unknown but may reflect the fact that the model employed in the present study is one of insulin-dependent diabetes. Moreover, unlike previous protocols, diabetic and normal rats in this study were deprived of food for 24-30 h before measurement of glucose Ra, a condition which served to markedly reduce the serum glucose concentration of the diabetic group to levels approximating those in food-deprived normal rats. A profound depressing effect of a prolonged period of food deprivation (72 h) on hepatic glucose production in the rat has been reported previously (1). Treatment of diabetic rats with CoCl2 resulted in ~50% reduction in glucose Ra. If glucose Ra is decreased by a similar extent under nonfasting conditions, then this change alone would be expected to result in a significant decrease in the glycemia of diabetic rats.
There was a tendency toward lower 2-deoxy-[14C]glucose uptake in tissues of CoCl2-treated rats, although only in the case of kidney and eye in diabetic rats was the decrease significant. It is possible that the marked reduction in glycemia of diabetic rats during the period of food deprivation results in a lower rate of tissue glucose uptake and thereby leads to a masking of any further decrement in glucose uptake by treatment with CoCl2. In keeping with this premise, it has been reported that food deprivation for 72 h in normal rats results in a decrease in sensitivity of peripheral tissues to the actions of insulin (1). Nevertheless, the summation of tissue uptake values, reflecting the uptake by the organism as a whole, is apt to be reduced in CoCl2-treated animals. It should also be noted that the decreased clearance of glucose from the circulation of diabetic rats treated with CoCl2 might help explain the finding that the glycemia of these rats is not lower than that of diabetic rats not treated with CoCl2.
Because the measurements of Ra and 2-deoxy-[14C]glucose uptake in various tissues were performed after a fasting period of 24-30 h, it is highly likely that Ra of glucose closely reflects gluconeogenesis rather than glycogenolysis. We therefore explored the possibility that treatment with CoCl2 reduces gluconeogenesis by the liver, a process that is controlled in part by the level of PEPCK activity (29). Because PEPCK activity closely parallels the level of its mRNA (13), we measured the relative abundance of PEPCK mRNA in livers of diabetic and normal rats treated with CoCl2. In accordance with previous findings, the abundance of PEPCK mRNA was increased in livers of diabetic rats compared with normal controls under nonfasting conditions (7). In addition, treatment with CoCl2 significantly reduced hepatic PEPCK mRNA levels in diabetic rats under fasting or nonfasting conditions. CoCl2 treatment also significantly reduced PEPCK mRNA levels in the livers of normal rats. However, a direct correspondence between PEPCK mRNA and hepatic glucose production may not always exist, especially under differing experimental and nutritional conditions. It is worth emphasizing that the decrease in PEPCK mRNA content does not represent a nonspecific or toxic effect of the agent because diabetic rats treated with up to 4 mM CoCl2 for 7 wk demonstrated no reduction in weight gain compared with diabetic controls not treated with CoCl2 (31), and the abundances of other mRNAs such as those encoding erythropoietin (8, 30) and GLUT-1 and GLUT-2 (31) are increased in CoCl2-treated rats.
The mechanism by which CoCl2
modifies the level of PEPCK mRNA in the livers of diabetic rats is of
interest. When CoCl2 is added to
cells in the presence of oxygen, many of its effects on gene expression
mimic the effects noted in response to lowered oxygen concentration
(8). For example, transcription of the gene coding for GLUT-1 is
stimulated in response to hypoxia by oxygen-sensing molecules that can
also be activated by cobalt (2). Cobalt is thought to alter gene
transcription by increasing the level of hypoxia-induced factor
(HIF)-1, a transcription factor that binds to a regulatory element
(CGTGCTG) in the promoter of a number of genes, most notably
erythropoietin and vascular endothelial growth factor genes (30). The
steady-state concentration of HIF-1 is induced by hypoxia or
CoCl2 by a mechanism that involves the stabilization of the protein against degradation, resulting in an
accumulation of the transcription factor (24). The gene for PEPCK has
also been shown to respond to changes in the redox state of liver cells
in culture (11). This gene is expressed in the liver in a decreasing
gradient from the periportal to the pericentral region (14), presumably
because of higher levels of oxygen and nutrients supplied to
hepatocytes in the periportal region. Previous studies by Hellkamp et
al. (11) have also demonstrated that glucagon-induced transcription
from the PEPCK promoter is inhibited by reducing the concentration of
oxygen from 16 to 8%. The hypoxia-inducible DNA element noted in the
3'-flanking region of the erythropoietin gene is also present in
the PEPCK promoter at 129 to
121 kb (from the
transcription start site), a position that is immediately 5' to a
control region that includes the cAMP and the nuclear factor-1
regulatory elements (
120 to
80 kb), which are critical
for both basal and cAMP-induced transcription of the PEPCK gene (18,
21). However, T. Kietzmann (personal communication) has implicated a
site in the PEPCK gene between
277 and
174 kb as being
required for the negative effect of redox state on transcription from
the PEPCK promoter in primary hepatocytes in culture (15). Although it
is possible that the effect of
CoCl2 noted in the present study
is due to an inhibition of transcription of the PEPCK gene in the liver
via a mechanism involving HIF-1, it is likely that there are multiple
elements in the PEPCK promoter involved in the effect of cobalt on
PEPCK gene expression.
Cytosolic PEPCK gene expression in the liver is highly controlled by a number of hormones and physiological conditions and most importantly by glucagon and insulin mediation of positive and negative regulation, respectively. Results of previous studies indicate that treatment with CoCl2 does not alter the concentration of insulin in the blood of normal rats (3, 31) and does not increase the extremely low levels of insulin in the blood of STZ-induced diabetic rats (31). It has also been reported that livers of CoCl2-treated nondiabetic rats are relatively "insensitive" to glucagon action, since the release of glucose by the liver in response to glucagon is decreased both in vivo and in vitro (4); the lower release of glucose is present, although the livers of CoCl2-treated rats contain higher levels of glycogen (3). Because of the critical regulation of PEPCK gene transcription by glucagon and cAMP, we elected to measure the levels of this nucleotide in liver of diabetic and normal rats treated or not treated with CoCl2. The results showed no systematic change among any of the groups examined except for the finding that food deprivation of normal rats resulted in a significant increase in the level of cAMP in the liver. It has been reported that CoCl2-treated rats appear to be more "sensitive" to the action of insulin in enhancing glucose disposal from the blood after a glucose load (3). If the liver of CoCl2-treated rats is also more sensitive to actions of insulin, then such a finding might help explain the lower glucose Ra in such animals. This explanation, however, cannot be extended to diabetic rats, given the extremely low levels of insulin in these animals. Further studies are required to gain a better understanding of the mechanisms mediating the apparent reduction of gluconeogenesis in CoCl2-treated diabetic and normal rats.
![]() |
ACKNOWLEDGEMENTS |
---|
This study was supported, in part, by grants from the Diabetes Association of Greater Cleveland and the National Institutes of Health (DK-45945 to F. Ismail-Beigi, DK-25541 to R. W. Hanson, and HD-11089 to S. C. Kalhan). P. Leahy and F. Saker were trainees on the National Institute of Diabetes and Digestive and Kidney Diseases Metabolism Training Grant DK-07319.
![]() |
FOOTNOTES |
---|
F. Saker and J. Ybarra contributed equally to this study.
Address for reprint requests: F. Ismail-Beigi, Clinical and Molecular Endocrinology, Case Western Reserve Univ., Cleveland, OH 44106-4951.
Received 22 October 1997; accepted in final form 20 February 1998.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Barzilai, N.,
D. Massiillon,
and
L. Rossetti.
Effects of fasting on hepatic and peripheral glucose metabolism in conscious rats with near-total fat depletion.
Biochem. J.
310:
819-826,
1995[Medline].
2.
Behrooz, A.,
and
F. Ismail-Beigi.
Dual control of GLUT1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation.
J. Biol. Chem.
272:
5555-5562,
1997
3.
Eaton, R. P.
Cobalt chloride-induced hyperlipemia in the rat: effects on intermediary metabolism.
Am. J. Physiol.
222:
1550-1557,
1972[Medline].
4.
Eaton, R. P.
Glucagon secretion and activity in the cobalt chloride-treated rat.
Am. J. Physiol.
225:
67-72,
1973[Medline].
5.
Elbrink, J.,
and
I. Bihler.
Membrane transport: its relation to cellular metabolic rates.
Science
188:
1177-1184,
1975[Medline].
6.
Ferré, P.,
A. Leturque,
A.-F. Burnol,
L. Penicaud,
and
J. Girard.
A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat.
Biochem. J.
228:
103-110,
1985[Medline].
7.
Friedman, J. E.,
J. S. Yun,
Y. M. Patel,
M. M. McGrane,
and
R. W. Hanson.
Glucocorticoids regulate the induction of P-enolpyruvate carboxykinase (GTP) gene transcription during diabetes.
J. Biol. Chem.
268:
12952-12957,
1993
8.
Goldberg, M. A.,
S. P. Dunning,
and
H. F. Bunn.
Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein.
Science
242:
1412-1415,
1988[Medline].
9.
Granner, D. K.,
T. Andreone,
K. Sasaki,
and
E. Beale.
Inhibition of transcription of the P-enolpyruvate carboxykinase gene by insulin.
Nature
305:
549-551,
1983[Medline].
10.
Hanson, R. W.,
and
Y. M. Patel.
Phosphoenolpyruvate carboxykinase (GTP): the gene and the enzyme.
Adv. Enzymol. Relat. Areas Mol. Biol.
56:
203-281,
1994.
11.
Hellkamp, J.,
B. Christ,
H. Bastian,
and
K. Jungermann.
Modulation by oxygen of the glucagon-dependent activation of the P-enolpyruvate carboxykinase gene in rat hepatocyte cultures.
Eur. J. Biochem.
198:
635-639,
1991[Abstract].
12.
Ismail-Beigi, F.
Metabolic regulation of glucose transport.
J. Membr. Biol.
135:
1-10,
1993[Medline].
13.
Iynedjian, P. B.,
and
R. W. Hanson.
Increase in the level of functional mRNA coding for P-enolpyruvate carboxykinase (GTP) during induction by cAMP.
J. Biol. Chem.
252:
655-662,
1977[Abstract].
14.
Jungermann, K.,
and
N. Katz.
Functional hepatocellular heterogeneity.
Hepatology
2:
385-395,
1982[Medline].
15.
Jungermann, K.,
and
T. Kietzmann.
Zonation of parenchymal and nonparenchymal metabolism in liver.
Annu. Rev. Nutr.
16:
179-203,
1996[Medline].
16.
Kalhan, S. C.,
K.-Y. Tserng,
C. Gilfillan,
and
L. J. Dierker.
Metabolism of urea and glucose in normal and diabetic pregnancy.
Metabolism
31:
824-833,
1982[Medline].
17.
Lamers, W. H.,
R. W. Hanson,
and
H. M. Meisner.
Cyclic AMP stimulates transcription of the gene for cytosolic phosphoenolpyruvate carboxykinase in rat liver nuclei.
Proc. Natl. Acad. Sci. USA
79:
5137-5141,
1982[Abstract].
18.
Liu, J.,
E. A. Park,
A. L. Gurney,
W. J. Roesler,
and
R. W. Hanson.
Cyclic AMP induction of P-enolpyruvate carboxykinase gene transcription is mediated by multiple promoter elements.
J. Biol. Chem.
266:
19095-19102,
1991
19.
Mercado, C. L.,
J. N. Loeb,
and
F. Ismail-Beigi.
Enhanced glucose transport in response to inhibition of respiration in Clone 9 cells.
Am. J. Physiol.
257 (Cell Physiol. 26):
C19-C28,
1989
20.
Mueckler, M.
Family of glucose-transporter genes. Implication for glucose homeostasis and diabetes.
Diabetes
39:
6-11,
1990[Abstract].
21.
Patel, Y. M.,
J. S. Yun,
J. Liu,
M. M. McGrane,
and
R. W. Hanson.
An analysis of regulatory elements in the PEPCK gene which are responsible for its tissue-specific expression and metabolic control in transgenic mice.
J. Biol. Chem.
269:
5619-5628,
1994
22.
Perriello, G.,
S. Pampanelli,
P. Del Sindaco,
C. Lalli,
M. Ciofetta,
E. Volpi,
F. Santeusanio,
P. Brunetti,
and
G. B. Bolli.
Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM.
Diabetes
46:
1010-1016,
1997[Abstract].
23.
Pessin, J. E.,
and
G. I. Bell.
Mammalian facilitative glucose transporter family: structure and molecular regulation.
Annu. Rev. Physiol.
54:
911-930,
1992[Medline].
24.
Salceda, S.,
and
J. Caro.
Hypoxia-inducible factor 1 (HIF-1
) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends on redox-induced changes.
J. Biol. Chem.
272:
22642-22647,
1997
25.
Shetty, M.,
N. Ismail-Beigi,
J. N. Loeb,
and
F. Ismail-Beigi.
Induction of GLUT1 mRNA in response to inhibition of oxidative phosphorylation.
Am. J. Physiol.
265 (Cell Physiol. 34):
C1224-C1229,
1993
26.
Shetty, M.,
J. N. Loeb,
and
F. Ismail-Beigi.
Enhancement of glucose transport in response to inhibition of oxidative metabolism: pre- and posttranslational mechanisms.
Am. J. Physiol.
262 (Cell Physiol. 31):
C527-C532,
1992
27.
Snedecor, G. W.,
and
W. G. Cochran.
Statistical Methods. Ames: Iowa Univ. Press, 1976.
28.
Tayek, J. A.,
and
J. Katz.
Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study.
Am. J. Physiol.
270 (Endocrinol. Metab. 33):
E709-E717,
1996
29.
Valera, A.,
A. Pujol,
M. Pelegrin,
and
F. Bosch.
Transgenic mice overexpressing PEPCK develop non-insulin-dependent diabetes.
Proc. Natl. Acad. Sci. USA
91:
9151-9154,
1994[Abstract].
30.
Wang, G. L.,
B. H. Jiang,
E. A. Rue,
and
G. L. Semenza.
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Proc. Natl. Acad. Sci. USA
92:
5510-5514,
1995[Abstract].
31.
Ybarra, J.,
A. Behrooz,
A. Gabriel,
M. H. Koseoglu,
and
F. Ismail Beigi.
Glycemia-lowering effect of cobalt chloride in the diabetic rat.
Mol. Cell. Endocrinol.
133:
151-160,
1997[Medline].
32.
Yoo-Warren, H.,
J. E. Monahan,
J. Short,
H. Short,
A. Bruzel,
A. Wynshaw-Boris,
H. M. Meisner,
D. Samols,
and
R. W. Hanson.
Isolation and characterization of the gene for cytosolic P-enolpyruvate carboxykinase (GTP) from the rat.
Proc. Natl. Acad. Sci. USA
80:
3656-3660,
1983[Abstract].
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |